Reports Q4 revenue $57,000, consensus $310,600. “The recent FDA acceptance of the dordaviprone NDA marks an important milestone for Chimerix (CMRX) and offers renewed hope for patients diagnosed with this life-threatening cancer,” said Mike Andriole, Chief Executive Officer of Chimerix. “Our mission to bring dordaviprone to patients globally is greatly enhanced by the pending acquisition of Chimerix by Jazz. We continue to prepare to bring dordaviprone to patients in need as quickly as possible.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMRX:
- Chimerix Hold Rating: Financial Constraints and Revised EPS Outlook Influence Cautious Recommendation
- Largest borrow rate increases among liquid names
- Jazz Pharmaceuticals price target raised to $230 from $220 at Truist
- Chimerix Stock Hold Rating: Limited Upside Due to Acquisition Offer Price Alignment
- Chimerix downgraded to Hold from Buy at JonesResearch